Immunogenicity Study of Biosimilar Candidates
Therapeutic proteins can induce undesirable immune reactions in the patient and constitute a major concern as they may compromise therapy safety and efficacy. During the comparability study between a biosimilar product and the innovator, several attributes are considered. Among them, the comparative...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2023
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/87684 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Immunogenicity Study of Biosimilar Candidates
- Biobetters: IFN-α2b Variants with Reduced Immunogenicity for the Treatment of Human Viral Diseases
- Rheumatic Diseases and Biosimilars: Evidence about Switch from Originators to Biosimilars in the Real Life
- HIV-1 Glycoprotein Immunogenicity
- Biosimilar Monoclonal Antibodies in Latin America
- Introductory Chapter: Biosimilars - A Regulatory and Clinical Perspective
- Low Immunogenic Potential of Human Neural Stem Cells